U.S. Markets closed

Today's Research Reports on Nuvo Pharmaceuticals, TSO3, Knight Therapeutics and CardioComm Solutions

NEW YORK, NY / ACCESSWIRE / June 15, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI Initiates Coverage on:

Nuvo Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=NRI.TO

TSO3 Inc.
https://rdinvesting.com/news/?ticker=TOS.TO

Knight Therapeutics Inc.
https://rdinvesting.com/news/?ticker=GUD.TO

CardioComm Solutions, Inc.
https://rdinvesting.com/news/?ticker=EKG.V

Nuvo Pharmaceuticals' stock moved 2.64% higher Thursday, to close the day at $2.72. The stock recorded a trading volume of 18,021 shares, which was above its three months average volume of 11,028 shares. In the last year, Nuvo Pharmaceuticals' shares have traded in a range of 2.65 - 4.65. The stock is currently trading 41.51% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $2.92 is below its 200-day moving average of $3.41. Shares of the company are trading at a Price to Earnings ratio of 21.94. Shares of Nuvo Pharmaceuticals have fallen approximately 26.49 percent year-to-date.

Access RDI's Nuvo Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NRI.TO

On Thursday, shares of TSO3 recorded a trading volume of 312,497 shares, which was above the three months average volume of 211,735 shares. The stock ended the day 10.31% higher at 1.07. The share price has gained 91.07% from its 52 week low with a 52 week trading range of 0.56 - 3.30. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.83 is below its 200-day moving average of $1.52. Shares of TSO3 have fallen approximately 59 percent year-to-date.

Access RDI's TSO3 Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TOS.TO

Knight Therapeutics' stock edged 0.75% higher Thursday, to close the day at $8.03. The stock recorded a trading volume of 113,656 shares, which was below its three months average volume of 137,768 shares. In the last year, Knight Therapeutics' shares have traded in a range of 7.38 - 10.43. The stock is currently trading 23.01% below its 52 week high. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $8.02 is greater than its 200-day moving average of $7.87. Shares of Knight Therapeutics are trading at a Price to Earnings ratio of 63.73. Shares of Knight Therapeutics have fallen approximately 3.37 percent year-to-date.

Access RDI's Knight Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=GUD.TO

On Thursday, shares of CardioComm Solutions recorded a trading volume of 290,000 shares, which was above the three months average volume of 144,703 shares. The stock ended the day flat at 0.05. The stock is currently trading 54.55% below its 52 week high with a 52 week trading range of 0.05 - 0.11. The company's shares are currently trading at their 200-day moving average. The stock's 50-day moving average of $0.05 is at its 200-day moving average of $0.05.

Access RDI's CardioComm Solutions, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=EKG.V

Our Actionable Research on Nuvo Pharmaceuticals Inc. (TSX :NRI.TO) and TSO3 Inc. (TSX :TOS.TO) and Knight Therapeutics Inc. (TSX :GUD.TO) and CardioComm Solutions, Inc. (TSXV :EKG.V) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com